Evidence map›Paper›PMID 25118937›Full record

ArticleCell death & disease2014

Depletion of intermediate filament protein Nestin, a target of microRNA-940, suppresses tumorigenesis by inducing spontaneous DNA damage accumulation in human nasopharyngeal carcinoma.

J Ma, F Sun, C Li, Y Zhang, W Xiao, Z Li, Q Pan, H Zeng, G Xiao, K Yao and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. MiR-940 Suppresses Ferroptosis by Controlling Expression of Key Regulatory Genes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Distribution, contribution and regulation of nestinJournal of advanced research · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

J Ma1] Institute of Genetic Engineering, Jinan University, National Engineering Research Center of Genetic Medicine, Key Lab for Genetic Medicine of Guangdong Province, Guangzhou, People's Republic of China [2] Central Laboratory, Shanghai 10th People's Hospital of Tongji University, Shanghai, People's Republic of China.
F SunDepartment of Medical Laboratory, Shanghai 10th People's Hospital of Tongji University, Shanghai, People's Republic of China.
C LiCancer Research Institute, Southern Medical University, Guangzhou, People's Republic of China.
Y ZhangCentral Laboratory, Shanghai 10th People's Hospital of Tongji University, Shanghai, People's Republic of China.
W XiaoCentral Laboratory, Shanghai 10th People's Hospital of Tongji University, Shanghai, People's Republic of China.
Z LiCancer Research Institute, Southern Medical University, Guangzhou, People's Republic of China.
Q PanCentral Laboratory, Shanghai 10th People's Hospital of Tongji University, Shanghai, People's Republic of China.
H ZengDepartment of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
G XiaoCancer Research Institute, Southern Medical University, Guangzhou, People's Republic of China.
K YaoCancer Research Institute, Southern Medical University, Guangzhou, People's Republic of China.
A HongInstitute of Genetic Engineering, Jinan University, National Engineering Research Center of Genetic Medicine, Key Lab for Genetic Medicine of Guangdong Province, Guangzhou, People's Republic of China.
J AnCancer Research Institute, Southern Medical University, Guangzhou, People's Republic of China.
Southern Medical University · CNTongji University · CNJinan University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a major malignant tumor of the head and neck region in southern China. The understanding of its underlying etiology is essential for the development of novel effective therapies. We report for the first time that microRNA-940 (miR-940) significantly suppresses the proliferation of a variety of cancer cell lines, arrests cells cycle, induces caspase-3/7-dependent apoptosis and inhibits the formation of NPC xenograft tumors in mice. We further show that miR-940 directly binds to the 3'-untranslated regions of Nestin mRNA and promotes its degradation. Likewise, depletion of Nestin inhibits tumor cell proliferation, arrest cells at G2/M, induces apoptosis and suppresses xenograft tumor formation in vivo. These functions of miR-940 can be reversed by ectopic expression of Nestin, suggesting that miR-940 regulates cell proliferation and survival through Nestin. Notably, we observed reduced miR-940 and increased Nestin levels in NPC patient samples. Protein microarray revealed that knockdown of Nestin in 5-8F NPC cells alters the phosphorylation of proteins involved in the DNA damage response, suggesting a mechanism for the miR-940/Nestin axis. Consistently, depletion of Nestin induced spontaneous DNA damage accumulation, delayed the DNA damage repair process and increased the sensitivity to irradiation and the chemotherapeutic agent doxorubicin. Collectively, our findings indicate that Nestin, which is downregulated by miR-940, can promote tumorigenesis in NPC cells through involvement in the DNA damage response. The levels of microRNA-940 and Nestin may serve as indicators of cancer status and prognosis.

Indexed as

DNA DamageAnimalsAntibiotics, AntineoplasticApoptosisBase SequenceCarcinomaCell Line, TumorCell ProliferationCell Transformation, NeoplasticDNA RepairDoxorubicinFemaleG2 Phase Cell Cycle CheckpointsGamma RaysHumansMiceAntibiotics, AntineoplasticDoxorubicinMicroRNAsMIRN940 microRNA, humanNestin

Identifiers

PMID25118937
PMCPMC4454294
OpenAlexW2042183442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.